Startseite Kongressberichte 2021 63rd ASH Annual Meeting and Exposition In-Person/Virtual MDS Low Risk Myelodysplastic Syndrome Prognosis and Treatment

637. Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment

61
Molecular International Prognosis Scoring System for Myelodysplastic Syndromes

Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, et al.

The IPSS-M risk score can be described as continuous, interpretable, and reproducible. It integrates information from 38 gene mutations. This leads to improved discrimination compared to the IPSS-R score. In addition, the IPSS-M risk score restratifies almost half of the MDS patients.

 

62
Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Marie Sebert, Thomas Cluzeau, Odile Beyne Rauzy, et al.

Ivosidenib achieved a significant response in MDS patients, with 91 percent particularly high in treatment-naive MDS patients at higher risk and IDH1 mutations (cohort B). Ivosidenib was well tolerated in all cohorts. Results of the molecular monitoring of IDH1 mutations will be presented in the oral session.

 

63
Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Lionel Ades, Sophie Dimicoli-Salazar, Marie Sebert, et al.

Enasidenib in patients with MDS does not show any limiting toxicity. 42 percent of patients respond to treatment. This response is particularly encouraging in first-line (low and high-risk) patients. Updates to the study are presented in the oral session.

 

 

64 ASH denotes this abstract as clinically relevant
The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry – a Prospective Cohort Study By the AGMT Study Group

Lisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.

See abstract for more info.

 

65
Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial

Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, et al.

In evaluable patients with MDS with a low / int risk, lenalidomide plus eltrombopag demonstrate an ORR of just under 41 percent and with a sustained response. The security profile is acceptable. See more info in the abstract.

 

66 ASH denotes this abstract as clinically relevant
Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Guillermo Garcia-Manero, James K McCloskey, Elizabeth A. Griffiths, et al.

An oral fixed-dose combination of decitabine/cedazuridine showed an equivalent PK exposure of 20 mg / m2 IV DEC in MDS patients and led to mlFS and mOS of more than 32 months. For MDS patients with lower risk and indicated treatment, the active ingredient was generally well tolerated after prolonged treatment.